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Abstract
Introduction
Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder primarily
affecting children and adolescents. It can lead to chronic pain, bony deformities and fractures.
The pathophysiology of CNO is incompletely understood. Scientific evidence suggests dysregu-
lated expression of pro- and anti-inflammatory cytokines to be centrally involved. Currently,
treatment is largely based on retrospective observational studies and expert opinion. Treatment
usually includes nonsteroidal anti-inflammatory drugs and/or glucocorticoids, followed by a
range of drugs in unresponsive cases. While randomised clinical trials are lacking, retrospective
and prospective non-controlled studies suggest effectiveness of TNF inhibitors and bisphospho-
nates. The objective of the Bayesian consensus meeting was to quantify prior expert opinion.
Methods
Twelve international CNO experts were randomly chosen to be invited to a Bayesian prior
elicitation meeting.
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Results
Results showed that a typical new patient treated with pamidronate would have an 84%
chance of improvement in their pain score relative to baseline at 26 weeks and an 83%
chance on adalimumab. Experts thought there was a 50% chance that a new typical patient
would record a pain score of 28mm (pamidronate) to 30mm (adalimumab) or better at 26
weeks. There was a modest trend in prior opinion to indicate an advantage of pamidronate
vs adalimumab, with a 68% prior chance that pamidronate is superior to adalimumab by
some margin. However, it is clear that there is considerable uncertainty about the precise
relative merits of the two treatments.
Conclusions
The rarity of CNO leads to challenges in conducting randomised controlled trials with suffi-
cient power to provide a definitive outcome. We address this using a Bayesian design, and
here describe the process and outcome of the elicitation exercise to establish expert prior
opinion. This opinion will be tested in the planned prospective CNO study. The process for
establishing expert consensus opinion in CNO will be helpful for developing studies in other
rare paediatric diseases.
Introduction
Chronic nonbacterial osteomyelitis (CNO) is a rare bone disorder producing sterile inflamma-
tory lesions. While some patients show timely limited monofocal disease, others will develop
chronically active or recurrent courses with multifocal bone involvement, which is then
referred to as chronic recurrent multi-focal osteomyelitis (CRMO) [1]. Primarily affecting
children and adolescents, CNO/CRMO is characterized by the insidious onset of bone pain
that may be severe and disabling, potentially leading to permanent damage [2].
The molecular pathophysiology is poorly understood. Currently, CNO is widely considered
to be an autoinflammatory disorder characterised by imbalanced expression of pro- and anti-
inflammatory cytokines [3–7]. Currently available treatment is based on case reports, retro-
spective or uncontrolled prospective case collections and expert opinion. Treatment strategies
for children with CNO/CRMO vary widely. Initially, treatment often includes nonsteroidal
anti-inflammatory drugs (NSAIDS) and/or glucocorticoids. Where these treatments are inef-
fective, a range of drugs have been tried including: bisphosphonates, sulfasalazine, methotrex-
ate and anti-TNF agents [3–15]. Among these options, the bisphosphonate pamidronate and
TNF inhibitors are considered most effective [3–15].
Pro-inflammatory TNF-α is involved in the differentiation and activation of osteoclasts,
which potentially centrally contributes to bone inflammation in CNO/CRMO. Thus, TNF
inhibition may (at least partially) correct cytokine imbalance in CNO. Indeed, several reports
indicate successful use of anti-TNF treatment in the management of CNO patients, including
patients who were refractory to pamidronate [8, 16].
The mechanism of action of bisphosphonates is uncertain [16]. The current hypothesis is
that bisphosphonates inhibit pathologically activated osteoclasts and may (partially) correct
imbalanced cytokine expression in CNO/CRMO [16].
Based on aforementioned retrospective reports, observational studies and expert opinion,
consensus treatment plans were developed by the North American Childhood Arthritis &
Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design
PLOS ONE | https://doi.org/10.1371/journal.pone.0215739 June 5, 2019 2 / 16
preparation of the manuscript. LVH’s contribution
to this work was made whilst she was an employee
of Lancaster University and was funded by the
Medical Research Council (grant MR/J014079/1).
The contributions of DV and IW were funded by the
Medical Research Council (IW grant MR/M013510/
1; DV grant Arthritis Research UK £21,010.36). PJF
is funded by the National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS) from
the National Institutes of Health (NIH)
R01AR059703.
Competing interests: The authors have declared
that no competing interests exist.
Rheumatology Research Alliance (CARRA) group [17]. However, to date, there have been no
published randomised controlled trials (RCTs) in CNO/CRMO. Indeed, phase III RCTs in
CNO/CRMO are unlikely to be feasible at this point in time, since patients are rare, prelimi-
nary reports suggest efficacy of anti-inflammatory treatment, and the absence of financial
incentives to industry. To generate urgently needed reliable evidence for safety and efficacy of
anti-inflammatory treatment in CNO, we propose that a Phase II study, randomising CNO/
CRMO patients aged 6 to 18 years to either pamidronate or adalimumab treatment. On the
basis of feasibility analyses, it is expected that approximately 40 children and young adults with
CNO/CRMO could be recruited across a UK network of 12 centres in two years. It is likely
that on the basis of such a sample size, a conventional hypothesis testing trial would have low
power to reliably detect a difference between treatments. However, this sample size is large
enough to be clinically relevant. With this in mind, we propose a Phase II trial to be performed
using Bayesian trial design [18].
Bayesian design is an innovative approach to clinical studies in small, but potentially diverse
patient populations [18]. There is growing interest in such approaches to facilitate the design
and interpretation of trials, as evidenced by the recent Food and Drug Administration (FDA)
workshop on this topic [19]. In the rare disease setting, by the time an RCT is planned, off-
label prescribing of the medicine of interest may already be underway. The Bayesian approach
can be used to formally augment data from a new RCT with clinicians’ prior understanding of
each medicine’s efficacy and safety. This understanding may be informed by several sources,
including the clinicians’ own prescribing experience, as well as existing published evidence.
An essential first step in a Bayesian trials is to carefully record available knowledge before the
new RCT begins. Many approaches have been proposed for eliciting experts’ individual opin-
ions and for aggregating them to summarise the position of a group [20–22]. We followed the
approach adopted for the MYPAN trial in polyarteritis nodosa [23, 24] and convened a face-
to-face meeting of Paediatric Rheumatologists experienced in treating CNO/CRMO and rec-
ognized as national and/or international experts. We used behavioural aggregation to establish
consensus prior distributions that will underpin a future Phase II trial in CNO/CRMO.
Methods
Establishing a group of experts to determine consensus prior opinion
A one-day consensus meeting was organised to bring together an international group of CNO/
CRMO experts from Europe and North America. We defined an expert as a clinician who: a)
had a documented interest in CNO/CRMO and would consider themselves to be a local
expert; b) was a consultant-grade clinician and specialist in paediatric rheumatology or ortho-
paedics; c) had treated at least 10 cases of CNO/CRMO in the last three years. Available fund-
ing permitted the attendance of thirteen experts at the consensus meeting. Attendance by two
internationally recognised leading CNO/CRMO researchers based in North America (PF, RL)
was considered essential to ensure that the wider research community would adopt the even-
tual outcome of the consensus meeting. Within these constraints, we set out to identify six fur-
ther clinicians from the UK and Ireland, and four clinicians from the rest of Europe who
satisfied our expert criteria and could attend in-person a one-day meeting in London, UK on
1st July 2016.
To identify potential experts, targeted enquiries were sent to research groups known to be
highly active in CNO/CRMO research which had published in high impact peer-reviewed
medical journals (PubMed journals with Impact Factor>/ = 4.0) in the last five years (2011–
2016). Such groups were invited to nominate a member to be considered for the meeting. In
addition, e-mails were circulated to members of the British Society of Paediatric and
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Adolescent Rheumatology (BSPAR; http://www.rheumatology.org.uk/bspar/) and the Paediat-
ric Rheumatology European Society (PRES; http://www.pres.eu) inviting expressions of inter-
est. All respondents were asked to complete an electronic survey confirming that they met the
stated criteria for meeting participation.
A priori it was agreed that meeting participants would be randomly selected from the group
of eligible experts identified through the process described above. Selection followed a pre-
specified protocol which stipulated that six experts, representing different centres, would be
randomly selected from the UK and Ireland, while four experts from different countries would
be randomly selected from the rest of Europe. All participants volunteered to take part in the
prior elicitation meeting as experts. No patients were involved in the meeting. Ethics approval
was therefore not required.
Process of establishing consensus prior opinion
The meeting took place in London on 1st July 2016 and proceeded according to the agenda
listed in Table 1, which itself emulates the agenda of the prior elicitation meeting performed
for the MYPAN trial in polyarteritis nodosa [24]. Prior to the elicitation meeting, experts were
sent preparatory reading material which comprised a summary of the key elements that would
feature in the protocol of a future CRMO trial. The meeting then began with a recap of this
material and an overview of the diagnosis of CRMO and existing information supporting the
use of pamidronate and adalimumab in the management of CRMO (drawn from two retro-
spective reviews of: a) 11 children with a CNO diagnosis who had received pamidronate ther-
apy [25]; b) a US cohort of 70 children diagnosed with CNO, of whom 11 were treated with
anti-TNF agents [26]). Other training sessions during the elicitation meeting covered the clini-
cal motivation for a future CRMO trial and its potential design. An introduction to the Bayes-
ian approach and a practical, interactive, example of the prior elicitation process was also
provided by a statistician with experience of Bayesian clinical trials.
Table 1. Activities comprising the consensus meeting and the time dedicated to each.
Time
allocation
(minutes)
Activity
• 30
Overview
• Introduction to the planned CRMO trial and the scope of the elicitation meeting
• 30
• 30
Training on Bayesian statistics
• Seminar introducing the Bayesian approach and how it can be used to represent prior opinion.
• Practical providing experts with an opportunity to describe their own uncertainty in the context
of a non-substantive example.
• 30
Clinical overview of existing CRMO treatment options
• Review of current treatment options for CRMO and what is known about them
• 15
Rationale for the Bayesian CRMO trial design
• Discuss rationale for adopting Bayesian design for CRMO trial
• 90
• 30
• 60
• 30
Formal elicitation exercise
• Each expert completes an individual elicitation questionnaire, then meets with a statistical
facilitator to visualise the prior corresponding to their stated answers. This process is iterated until
the expert is content that the prior reflects their underlying beliefs.
• Present to the group all individuals’ answers to the ten primary elicitation questions (QP1-QP5
and QA1-QA5 listed in S1 Appendix).
• Convene structured discussions to identify consensus answers to QP1-QP5 and QA1-QA5. If a
consensus cannot be reached, characterise the conflicting opinions of the distinct expert
subgroups.
• Present visualisations and summaries of the prior distributions corresponding to consensus
answers (if these can be established). Establish the validity of these priors as representing the
consensus prior opinion of the group.
https://doi.org/10.1371/journal.pone.0215739.t001
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The afternoon was devoted to the formal elicitation process, structured so that the opinions
of individuals were established before attempting to reach a consensus [27]. We adopted this
structure to reduce the risk of experts being unduly influenced by overconfident group mem-
bers or those with strong personalities. Four facilitators with statistical training were on hand
throughout to facilitate (LVH, APJ, DV and IW). Each expert was first asked to complete a
structured questionnaire before having a one-to-one meeting with a facilitator. The facilitator
took the expert’s answers to ten questions and fed back visualisations and summaries of the
consequences of the stated beliefs: the expert was permitted to refine his/her initial answers
until priors with face validity could be obtained. Once each expert’s individual opinions had
been finalised, these were displayed to the group and each expert was invited to comment on
his or her answers. Structured discussions ensued, moderated by the two chief clinical investi-
gators (AVR, MWB) and a statistical facilitator (LVH). During these discussions, experts were
permitted to update their answers to the 10 key elicitation questions, although only one expert
took advantage of this opportunity. Finally, we used the approach outlined in section ‘Estab-
lishing consensus expert opinion’ to identify consensus answers to the ten primary elicitation
questions, which the majority could adopt as adequate reflections of their prior beliefs. These
consensus opinions, and their consequences, are detailed below.
Statistical approach for establishing Bayesian prior distributions
Defining the quantities to be elicited
The primary endpoint of a future Phase II CNO/CRMO trial will be change in pain score from
baseline at 26 weeks, measuring pain scores on a 100 mm visual analogue scale (VAS). We
assumed that patient outcomes will follow a Gaussian ‘bell-shaped’ distribution, with a com-
mon variance across treatment arms. This is a pragmatic model since it does not adjust for
baseline scores. Neither does it formally account for the fact that pain scores must lie between
0 and 100 mm, although it should be reasonably accurate as long as pain scores do not tend to
lie too close to either boundary. Denoting by μP the average outcome that would be observed
across a large number of patients randomised to pamidronate, we can express the correspond-
ing average outcome on adalimumab as μP + δ. Thus δ, which is the difference between average
outcomes on adalimumab and pamidronate, is the ‘treatment effect’ of interest. Since a nega-
tive change in pain score implies that a patient’s symptoms have improved from baseline, a
negative value for δ is consistent with adalimumab having superior efficacy relative to pami-
dronate, and vice versa. We refer to the common variance of patient outcomes as 1/τ.
Together, μP, δ and τ define the likelihood of observing any potential dataset from the
future CRMO trial. The objective of the Bayesian consensus meeting was to quantify prior
opinion on these three quantities. Once data from a future CRMO trial become available,
Bayes Theorem will be used to update this prior opinion to obtain posterior distributions rep-
resenting the totality of what has been learnt about the relative merits of pamidronate and
adalimumab.
Statistical model for expert prior opinion
We adopted a ‘conjugate’ model for prior opinion on the three quantities (μP, δ and τ) defined
above, so-called because posterior distributions incorporating trial data will be of the same sta-
tistical form as the prior distributions. Specifically, we assumed that prior opinion on τ could
be modelled as a gamma distribution with shape and rate parameters a0 and b0, respectively.
Furthermore, we assumed that if the true value of τ were known, in light of this knowledge
prior opinion on μP and δ would follow a (2-dimensional) Gaussian distribution with mean
vector (μP0, δ0) and variance-covariance matrix (1/τ)R. The prior means μP0 and δ0 represent
Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design
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what consensus best guesses at μP and δ would be in light of τ, while the variance-covariance
matrix quantifies uncertainty about these guesses and the correlation of opinion on the two
parameters.
Given an expert’s prior opinion on μP, δ and τ, one can derive their predictive distribution
for the response of a future patient randomised to either pamidronate or adalimumab. An
expert’s uncertainty about how a future individual patient will respond reflects uncertainty
arising due to sampling variability (i.e., two patients given the same treatment will respond dif-
ferently) and the expert’s imperfect prior understanding of the data generating parameters.
Further details on the proposed statistical model for data from a future CRMO trial, and expert
prior opinion on the three key statistical parameters, can be found in S1 Appendix.
Establishing expert opinion
It would be a challenging and complex task to elicit expert opinion directly on μP, δ and τ.
Instead we took a different approach, characterising opinion on these quantities by asking
experts a sequence of ten questions to establish their opinion on the change in pain score that
would be observed if a new patient were treated with either pamidronate or adalimumab for
26 weeks according to the proposed trial protocol. Five questions concerned a patient’s
response after treatment with pamidronate; five concerned adalimumab. The 10 questions
were initially drafted by a statistician (LVH) and were then critically reviewed by clinical mem-
bers of the team (AR, MWB) to check for clarity of language and meaning. The complete ques-
tionnaire is provided in S1 Appendix. To make elicitation questions more concrete, experts
were asked to consider a typical patient who presents at baseline with a pain score of 60 mm,
and to give their opinion on the pain score that this patient would record after 26 weeks of
treatment. From this, opinion on the change from baseline could be derived. We then deduced
the prior distributions for μP, δ and τ that would be most consistent with the expert’s stated
opinions on how a future patient would respond. A bespoke web application, written in R [28]
using the Shiny package [29], was developed to facilitate the elicitation process. It takes an
expert’s answers to the ten elicitation questions and feeds back graphical and descriptive sum-
maries of fitted prior distributions. The software is freely available from the authors upon
request.
To obtain a more complete understanding of each expert’s opinions, they were also asked
to complete a table, assigning to a number of intervals weights representing the strength of
their belief that a new typical patient’s 26-week pain score on pamidronate would lie in that
interval. A similar table was completed for adalimumab. The tables which appear in questions
P6 and A6 were adapted from those used by White et al [30] in their elicitation exercise for the
CHARM trials (although the parameters of interest in that example were quite different to
those of interest for the CRMO trial). This process also enabled statistical facilitators to verify
the consistency of an expert’s answers to earlier elicitation questions.
Establishing consensus expert opinion. To deduce prior distributions for μP, δ and τ
which reflected the group’s consensus position, we adopted the following dynamic strategy.
We used as a starting point the priors implied by the arithmetic means of the experts’ final
individual answers to the 10 key elicitation questions, and fedback to the group visualisations
and summaries of these distributions to confirm their acceptability. If they were deemed to be
unsuitable as consensus priors, our next step would be to identify why and explore a range of
alternative distributions created by modifying the mean elicitation answers appropriately. This
approach seemed reasonable in light of our experiences with the MYPAN prior elicitation
exercise [23]. Furthermore, taking the mean of the individual elicitation answers is a natural
starting point when there is little variation between the experts’ stated individual opinions.
Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design
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However, when defining consensus priors for each parameter, we were also prepared to
respond dynamically to the group discussions. For example, if it became clear that a consensus
position would not be possible or that our statistical model for expert opinions was fitting
poorly, we would document the expert’s individual answers to the elicitation questions and the
group discussion, and then consider next steps off-line.
Evaluating the operating characteristics of a future CNO/CRMO trial
To explore the impact that data from a future CNO/CRMO trial randomising 20 patients to
each treatment arm would have on expert opinion, we investigated how the consensus priors
would be updated by three hypothetical trial datasets. Each hypothetical dataset was summa-
rised by its corresponding estimates of mean changes from baseline on adalimumab and pami-
dronate (�xA and �xP, respectively), and the pooled outcome variance estimate (s
2). These
summaries are ‘complete’ in the sense that any two trials with individual patient data leading
to the same values of these estimates would produce the same posterior distributions. The
three hypothetical datasets were specified after the consensus priors had been formally agreed
upon at the elicitation meeting. One dataset was stipulated so as to be consistent with the con-
sensus priors. The remaining datasets were designed to conflict with the consensus prior
opinion.
To quantify the operating characteristics of a CNO/CRMO trial recruiting 20 patients to
each treatment arm, we performed a simulation study. Data were simulated under the six sce-
narios listed in Table 2, assuming patient outcomes followed the normal linear model
described in Section ‘Defining the quantities to be elicited’. We considered three scenarios for
the average change from baseline pain score at 26 weeks on pamidronate:
A. μP is equal to the mode of its consensus prior
B. μP = -40mm (i.e. 24% smaller than its prior mode; pamidronate more effective than
expected)
C. μP = -26mm (i.e. 20% larger than its prior mode; pamidronate less effective than expected).
These scenarios were chosen to capture a range of values for μP which looked plausible in
light of the experts’ consensus prior opinion and which rounded to whole numbers (for
convenience).
In scenarios A-C, responses on adalimumab were simulated under two different cases for
the treatment effect: i) no treatment effect, in which case the average change from baseline on
Table 2. Data simulation scenarios. Data stimulation scenarios in which: μP (or μA) denotes the true long-run aver-
age change from baseline pain score at 26 weeks on pamidronate (or adalimumab); σ is the common standard devia-
tion of change from baseline pain scores.
True average change from baseline on
pamidronate
True difference between average changes from baseline at 26 weeks
on pamidronate and adalimumab
No difference Pamidronate superior by clinically
relevant margin
Scenario A μP = -32.3, μA = -32.3, σ
= 9.3
μP = -32.3, μA = -24.9, σ = 9.3
Scenario B μP = -40, μA = -40, σ =
11.5
μP = -40, μA = -30.8, σ = 11.5
Scenario C μP = -26, μA = -26, σ =
7.5
μP = -26, μA = -20, σ = 7.5
https://doi.org/10.1371/journal.pone.0215739.t002
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adalimumab is equal to μP; ii) a clinically relevant treatment effect, in which case the average
change from baseline on pamidronate is 30% smaller than the average change on adalimumab.
On completion of each simulated trial we calculated the posterior probability that either pami-
dronate is beneficial on average and superior to adalimumab by the clinically relevant margin
defined above; or adalimumab is beneficial and superior to pamidronate by a clinically rele-
vant margin. In each of the six simulation scenarios, we recorded the proportion of 1,000 sim-
ulated trials in which this posterior probability exceeded 0.2. All simulations were run in R
using the OpenBUGS [31] software to implement the Bayesian analysis.
Results
Fifty-one clinicians from across Europe, Turkey and Russia who completed the electronic sur-
vey, registered their interest in attending the CNO/CRMO consensus meeting, 32 of whom
met predefined “expert criteria”. Three experts were based in Turkey or Russia, and due to
funding constraints were not considered further for participation in the meeting. Fifteen of the
remaining eligible experts, representing eleven clinical centres, were based in the UK (fourteen
experts) or Ireland (one expert). These experts were first listed in alphabetical order; in cases
where more than one expert had the same affiliation, only the expert occurring highest in the
alphabetical ordering was retained. From the reduced listing of eleven experts thus compiled,
six were randomly selected (BJ, JD, AK, OGK, SCL, MR): three of these experts represented a
centre that had more than one volunteer. In these cases, all of the experts from that centre
were contacted and invited to nominate a single representative to attend the consensus
meeting.
The remaining 14 eligible experts from the rest of Europe were based in nine countries,
namely, Denmark (2 experts), France (1), Germany (5), Greece (1), Italy (1), Netherlands (1),
Spain (1), Sweden (1) and Switzerland (1). From these countries, we randomly selected four
(Denmark, Germany, Greece, Netherlands) and then one expert per selected country (TH, JS,
DV, CH). In addition to the two key opinion leaders invited from North America, shortly
prior to the consensus meeting, funding became available to cover the travel expenses of an
additional UK-based expert (MR). Therefore, in total twelve experts attended the meeting, all
of whom are included as co-authors on this manuscript.
Consensus opinion
Table 3 lists answers of the thirteen experts to the ten principal elicitation questions (labelled
QP1-5 and QA1-5). The group accepted as their consensus answers to these questions the
arithmetic means of their individual answers. Consensus opinion was that a typical new
patient treated with pamidronate would have an 84% (chance of registering some improve-
ment in his/her pain score relative to baseline at 26 weeks and an 83% chance when treated
with adalimumab. Experts thought there was a 50% chance that a new typical patient on pami-
dronate would record a pain score of 28 mm or better at 26 weeks and a pain score of 30 mm
on adalimumab. These answers reflect the general opinion that a typical patient’s 26-week pain
score would be broadly similar after treatment with pamidronate or adalimumab.
Experts’ final answers to ten structured elicitation questions asking for opinion on the pain
score of a typical patient after 26 weeks of treatment with either pamidronate or adalimumab
according to the proposed CRMO protocol. The wording of the elicitation questions is listed
in S1 Appendix. The arithmetic means of answers were proposed and accepted by the group as
summaries of its consensus opinion.
Prior distributions for: a) the response of a future individual patient; b) the average change
in pain score on pamidronate; and c) the difference between average changes in pain score on
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adalimumab and pamidronate, corresponding to these ten consensus answers were then
derived, and visualisations and summaries of the priors fed back to the group. Experts agreed
to adopt these proposals as the group’s consensus prior distributions.
Fitted prior distributions corresponding to consensus answers are shown in (Fig 1). (Fig
1A) plots fitted predictive distributions for a new typical patient’s change in pain score at 26
weeks. Due to the pragmatic nature of the Bayesian outcome model, fitted predictive distribu-
tions place prior weight on changes ranging between +/- 100mm, but place negligible weight
on values outside this range. Percentiles of the fitted prior predictive distributions for a new
typical patient’s change in pain score at 26 weeks (shown as solid plotting symbols) are close to
the experts’ stated beliefs (indicated by open symbols) for both treatments.
Impact of consensus opinion on planned clinical trial
Three hypothetical datasets from a future CRMO trial randomising 40 patients between pami-
dronate and adalimumab were defined as follows:
• Hypothetical dataset 1: s2 = 4.6, �xA = -30, �xP = -30. These estimates are broadly consistent
with consensus prior opinion.
• Hypothetical dataset 2: s2 = 21.3, �xA = -30, �xP = -20. The variance estimate is larger than
would be expected from prior opinion; the estimated mean outcome on pamidronate is dis-
appointing; adalimumab is more effective than pamidronate.
• Hypothetical dataset 3: s2 = 4.6, �xA = -10, �xP = -20. The variance estimate is consistent with
prior opinion, while the estimated mean outcomes on both treatments are disappointing,
although pamidronate is more effective than adalimumab.
When interpreting the outcome variance estimate, we note that 4.6 mm is the 75th percen-
tile of the consensus prior distribution for the outcome variance, while
p
(21.3) is twice the
prior modal estimate of the treatment difference.
(Fig 2A–2D) illustrate how consensus prior opinion on the true average changes in pain
score on each treatment, and their difference, would be updated by each hypothetical dataset.
Table 3. Expert responses to elicitation questions.
Expert Pamidronate Adalimumab
QP1 QP2 QP3 QP4 QP5 QA1 QA2 QA3 QA4 QA5
1 75 50 40 5 0 80 40 35 5 0
2 85 25 15 10 5 80 30 25 20 15
3 80 40 30 20 10 70 50 40 30 20
4 90 40 30 20 10 85 45 35 25 15
5 90 35 25 20 15 75 45 35 25 20
6 95 40 20 5 2 75 60 40 15 5
7 85 40 30 20 10 75 50 40 30 10
8 90 50 40 30 20 95 50 35 20 10
9 90 40 30 20 10 95 35 25 15 5
10 90 65 30 20 10 95 60 30 20 10
11 80 50 20 5 0 80 60 30 20 4
12 85 40 20 0 0 95 20 10 0 0
13 60 40 30 25 15 80 15 10 5 0
Mean 84.2 42.7 27.7 15.4 8.2 83.1 43.1 30 17.7 8.8
Median 85 40 30 20 10 80 45 35 20 10
https://doi.org/10.1371/journal.pone.0215739.t003
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Comparing prior and posterior densities, it is clear that data on 40 patients would have an
important impact on the current consensus understanding of the effects of pamidronate and
adalimumab in CNO/CRMO patients. Posterior densities become more peaked, attributing
plausibility to a smaller range of parameter values. In addition, data on 40 patients will be able
to shift prior opinion in the event that they are inconsistent with beliefs represented by the
consensus priors.
Posterior densities for model parameters that would be obtained by updating consensus
prior distributions with hypothetical data on 40 patients.
The posterior 90% credible interval for the average change from baseline pain score at 26
weeks on adalimumab was (-30.8, -29.2) mm given hypothetical dataset 1; (-31.5, -28.3) mm
given hypothetical dataset 2; and (-10.8, -9.3) mm given hypothetical dataset 3.
The posterior 90% credible interval for the average change from baseline pain score at 26
weeks on pamidronate was (-30.8, -29.3) mm given hypothetical dataset 1; (-21.7, -18.5) mm
given hypothetical dataset 2; and (-20.7, -19.2) mm given hypothetical dataset 3.
The posterior 90% credible interval for the additional average change in pain score experi-
enced on adalimumab is (-1.0, 1.1) mm given hypothetical dataset 1; (-12.1, -7.5) mm given
hypothetical dataset 2; (8.8, 11.0) mm given hypothetical dataset 3.
The results of the simulation study in Table 4 show that the proposed Bayesian decision
rule would control the risk of incorrectly declaring a clinically relevant difference between
treatments when none exists at an acceptable level. In simulation scenario A, when there is a
clinically important difference between pamidronate and adalimumab, 76% of simulated trials
correctly declared a difference according to the proposed Bayesian decision rule. Similar prob-
abilities were also recorded in scenarios B and C.
Proportion of 1,000 simulated trials which concluded that there was evidence of a clinically
relevant difference in any direction between pamidronate and adalimumab. All simulated tri-
als allocated 20 patients to each treatment arm.
Discussion
There are no published RCTs comparing the relative effectiveness of adalimumab and pami-
dronate in treating children with CNO/CRMO [8, 16]. The rarity of CNO/CRMO leads to sig-
nificant challenges in conducting RCTs with sufficient power to provide a definitive outcome.
We proposed this using a Bayesian clinical trial design and have described the process and out-
come of the elicitation exercise to establish expert prior opinion. The process was done in a
structured format [27], led by a statistician experienced in Bayesian statistics (LVH), and
informed by a systematic review [32] providing principles for best practice in prior opinion
elicitation.
Importantly, the priors’ elicitation meeting with international experts in the field concluded
that a Bayesian RCT with data on 40 patients would have an important impact on the current
consensus understanding of the effects of pamidronate and adalimumab in CNO/CRMO
patients. Specifically, these data will be able to shift prior opinion in the event that they are
Fig 1. Consensus prior densities for outcome model parameters. (Fig 1B) shows consensus prior distributions for the average change in
pain scores at 26 weeks on pamidronate or adalimumab. Prior modal values for the average change in pain score on pamidronate and
adalimumab are -32.3 mm and -30 mm, respectively. (Fig 1C) displays the consensus prior for the treatment effect. Prior opinion is that
there is a 90% chance that the true difference between average change scores on adalimumab versus pamidronate lies between -6.9 mm and
11.5 mm (with a negative difference indicating an advantage for adalimumab). Furthermore, there is a 68.4% prior probability that
pamidronate is superior to adalimumab by any margin. However, it is clear that there is considerable uncertainty about the precise relative
merits of the two treatments. (Fig 1A), plotted symbols represent the experts’ consensus answers to elicitation questions QA2-5 and QP2-5
minus 60mm, which was the pain score assumed to characterise a typical patient at baseline.
https://doi.org/10.1371/journal.pone.0215739.g001
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Fig 2. Posterior densities for model parameters.
https://doi.org/10.1371/journal.pone.0215739.g002
Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design
PLOS ONE | https://doi.org/10.1371/journal.pone.0215739 June 5, 2019 12 / 16
inconsistent with beliefs represented by the consensus priors. Furthermore, the proposed
Bayesian decision rule will control the risk of incorrectly declaring a clinically relevant differ-
ence between treatments when none exists at an acceptable level.
The results of the experts Bayesian priors clearly demonstrated that there was consensus on
the equivocal efficacy of both agents considered in planned trial. There was significant agree-
ment that a trial as planned was required to help manage children and adolescents with this
condition. It is important to reflect that most of the experts manage children with CRMO on a
regular basis and understand the existing lack of clarity on appropriate treatment modalities
for these children. It is interesting to note that consensus treatment plans (CTPs) published by
the CARRA (Childhood Arthritis and Rheumatology Research Alliance) group demonstrate
similar therapeutic dilemma with both agents considered in our trial being considered as
equally effective based on limited existing evidence [33].
This exercise will now also allow us to embark on our planned study with priors informing
us of the need for this study and reaffirming the planned study design in light of existing evi-
dence base.
We acknowledge that inviting experts to volunteer in the process may impact on the type of
expert participating, possibly more likely to attract those more supportive of the trial or those
more critical of it. However, although using the face-to-face elicitation process may limit the
numbers of experts’ opinions that can be included; we felt it is important to ensure that the
process is highly interactive so that the process is effective in capturing the true opinion of the
experts as well as allowing structured group discussions. We have attempted to overcome this
through inviting experts over a wide range of locations using a clear and transparent expert
selection process. One limitation of the prior elicitation meeting is that we did not record
ahead of time the potential conflicts of interest (CoIs) of the experts who participated, and so
we are unable to comment on the potential impact these may have had on the opinions
expressed. The SHELF elicitation framework [34] recommends that experts record ahead of
the meeting any personal interests in the outcome of the elicitation exercise: the aim is not to
exclude experts with conflicts but rather to be completely transparent about them.
In conclusion, we have defined consensus prior opinion regarding the relative effectiveness
of adalimumab and pamidronate in reducing pain scores in children with CNO/CRMO. This
opinion will be tested in the planned CNO/CRMO clinical trial of adalimumab and pamidro-
nate. Demonstration of the effectiveness of the process for establishing expert consensus opin-
ion in rare diseases will be helpful for consideration of developing clinical trials in other rare,
paediatric diseases.
Supporting information
S1 Appendix. Questionnaire to elicit individual experts’ prior opinions.
(DOCX)
Table 4. Simulated trials.
True long-run average response on
pamidronate
True difference between average changes from baseline at 26
weeks
No difference Pamidronate superior by clinically relevant
margin
Scenario A 0.045 0.76
Scenario B 0.04 0.776
Scenario C 0.036 0.778
https://doi.org/10.1371/journal.pone.0215739.t004
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